Crescent Biopharma, Inc. (CBIO) — Quantitative Stock Analysis
Quantitative analysis for Crescent Biopharma, Inc. (CBIO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based return forecast, technical and fundamental signals, insider and institutional flow, and walk-forward validated accuracy.
Current Q-Score verdict: Sell (26.0) (grade D). 28 signals analyzed (22 differentiated alt-data).
Key Quantitative Facts
- Sector: Health Care
- Market Cap: $449M
- Price: $16.30
- Q-Score Verdict: Sell (26.0) grade D
- Insider Activity: 1 filers (14d)
- Signal Coverage: 28 signals (22 alt-data)
What StoQuant measures for CBIO
- AI-powered Alpha (Gem) Score combining 15+ fundamental, technical, and sentiment signals.
- Benjamin Graham intrinsic value and margin-of-safety vs. current price.
- Composite Q-Score blending DCF upside, earnings quality (Piotroski F, Altman Z), moat score, analyst consensus, ML probability, and social buzz.
- Walk-forward validated ML return forecasts with confidence intervals.
- Insider and institutional flow, short interest, and regime-aware portfolio context.
Access the full research
Detailed interactive charts, factor decomposition, and forecast bands are available to signed-in members. Learn more or view pricing.